NASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Forecast, Price & News $7.59 -0.05 (-0.65%) (As of 01:11 PM ET) Add Compare Share Share Today's Range$7.48▼$7.7050-Day Range$2.64▼$7.6452-Week Range$1.64▼$7.95Volume200,284 shsAverage Volume538,660 shsMarket Capitalization$507.54 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tenaya Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside148.7% Upside$18.75 Price TargetShort InterestBearish5.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingAcquiring Shares$17,625 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.98) to ($2.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.76 out of 5 starsMedical Sector743rd out of 980 stocksBiological Products, Except Diagnostic Industry117th out of 163 stocks 3.5 Analyst's Opinion Consensus RatingTenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.75, Tenaya Therapeutics has a forecasted upside of 148.7% from its current price of $7.54.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.04% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenaya Therapeutics has recently increased by 30.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TNYA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Tenaya Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $17,625.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders34.24% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tenaya Therapeutics are expected to decrease in the coming year, from ($1.98) to ($2.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tenaya Therapeutics (NASDAQ:TNYA) StockTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.Read More Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Stock News HeadlinesJune 3, 2023 | americanbankingnews.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by BrokeragesJune 2, 2023 | fool.comTenaya Therapeutics (NASDAQ: TNYA)June 5, 2023 | Edge On The Street (Ad)AI industry Is Exploding! New Breakthrough Expected this SummerBill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.May 30, 2023 | finance.yahoo.comWith 35% stake, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) seems to have captured institutional investors' interestMay 16, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Tenaya Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:TNYA)May 15, 2023 | finance.yahoo.comWall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to TradeMay 14, 2023 | americanbankingnews.comChardan Capital Trims Tenaya Therapeutics (NASDAQ:TNYA) Target Price to $23.00May 12, 2023 | msn.comChardan Capital Maintains Tenaya Therapeutics (TNYA) Buy RecommendationJune 5, 2023 | Edge On The Street (Ad)AI industry Is Exploding! New Breakthrough Expected this SummerBill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.May 12, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Tenaya TherapeuticsMay 12, 2023 | marketwatch.com8-K: Tenaya Therapeutics, Inc.May 11, 2023 | msn.comHC Wainwright & Co. Reiterates Tenaya Therapeutics (TNYA) Buy RecommendationMay 11, 2023 | finance.yahoo.comTenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's WhyMay 11, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Tenaya Therapeutics (TNYA)May 10, 2023 | finance.yahoo.comTenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 7, 2023 | americanbankingnews.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $19.00 Consensus PT from AnalystsMay 3, 2023 | finance.yahoo.comWe Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth CarefullyMay 3, 2023 | finance.yahoo.comTenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual MeetingMay 2, 2023 | marketwatch.comTenaya Therapeutics Gets FDA Fast-Track Designation for TN-201 >TNYAMay 2, 2023 | finance.yahoo.comTenaya Therapeutics Receives FDA Fast Track Designation for TN-201May 1, 2023 | msn.comUnusual Call Option Trade in Tenaya Therapeutics (TNYA) Worth $38.40KApril 21, 2023 | benzinga.comTenaya Therapeutics Stock (NASDAQ:TNYA), DividendsApril 19, 2023 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Could Rally to $40 (or More), Says Piper SandlerApril 14, 2023 | americanbankingnews.comBrokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Target Price at $19.00April 10, 2023 | seekingalpha.comTenaya Therapeutics Has Been An Early Stage Company For Too LongMarch 9, 2023 | markets.businessinsider.comLifeSci Capital Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)March 9, 2023 | finanznachrichten.deTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateSee More Headlines TNYA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNYA Company Calendar Last Earnings3/08/2023Today6/05/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNYA CUSIPN/A CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees106Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.75 High Stock Price Forecast$23.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+135.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.59% Return on Assets-49.42% Debt Debt-to-Equity RatioN/A Current Ratio8.01 Quick Ratio8.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.64 per share Price / Book2.10Miscellaneous Outstanding Shares66,870,000Free Float43,974,000Market Cap$510.89 million OptionableNot Optionable Beta2.44 Key ExecutivesMr. Faraz Ali M.B.A. (Age 49)CEO, Sec. & Director Comp: $710.77kDr. Deepak Srivastava M.D. (Age 55)Scientific Founder, Chairman of Scientific Advisory Board & Director Comp: $18.15kMs. Leone D. Patterson M.B.A. (Age 59)Chief Financial & Bus. Officer Comp: $448.55kDr. Whittemore G. Tingley M.D. (Age 54)PH.D., Chief Medical Officer Comp: $551.18kDr. Eric N. Olson Ph.D.Scientific Founder & Member of Scientific Advisory BoardDr. Bruce R. ConklinScientific FounderDr. Saptarsi Haldar M.D.Scientific FounderDr. Sheng DingScientific FounderDr. Benoit G. Bruneau Ph.D.Scientific FounderDr. Kee-Hong Kim Ph.D. (Age 56)Chief Technology Officer More ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATEAura BiosciencesNASDAQ:AURAAgenusNASDAQ:AGENVoyager TherapeuticsNASDAQ:VYGRIcosavaxNASDAQ:ICVXView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 14,600 shares on 6/1/2023Ownership: 0.037%JPMorgan Chase & Co.Bought 17,351 shares on 5/18/2023Ownership: 0.052%Rockefeller Capital Management L.P.Bought 30,000 shares on 5/17/2023Ownership: 0.045%State Street CorpBought 69,708 shares on 5/16/2023Ownership: 0.743%Susquehanna International Group LLPBought 21,300 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions TNYA Stock - Frequently Asked Questions Should I buy or sell Tenaya Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNYA shares. View TNYA analyst ratings or view top-rated stocks. What is Tenaya Therapeutics' stock price forecast for 2023? 6 Wall Street research analysts have issued 12-month target prices for Tenaya Therapeutics' shares. Their TNYA share price forecasts range from $13.00 to $23.00. On average, they anticipate the company's stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 145.4% from the stock's current price. View analysts price targets for TNYA or view top-rated stocks among Wall Street analysts. How have TNYA shares performed in 2023? Tenaya Therapeutics' stock was trading at $2.01 at the beginning of 2023. Since then, TNYA shares have increased by 280.1% and is now trading at $7.64. View the best growth stocks for 2023 here. Are investors shorting Tenaya Therapeutics? Tenaya Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,060,000 shares, an increase of 30.4% from the April 30th total of 1,580,000 shares. Based on an average daily trading volume, of 642,700 shares, the days-to-cover ratio is presently 3.2 days. Approximately 5.0% of the shares of the stock are short sold. View Tenaya Therapeutics' Short Interest. When is Tenaya Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our TNYA earnings forecast. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) released its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.05. What ETF holds Tenaya Therapeutics' stock ? BlackRock Future Health ETF holds 354 shares of TNYA stock, representing 0.04% of its portfolio. When did Tenaya Therapeutics IPO? (TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. What is Tenaya Therapeutics' stock symbol? Tenaya Therapeutics trades on the NASDAQ under the ticker symbol "TNYA." Who are Tenaya Therapeutics' major shareholders? Tenaya Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.56%), FMR LLC (5.62%), BlackRock Inc. (4.17%), Regents of The University of California (1.44%), Geode Capital Management LLC (1.18%) and State Street Corp (0.74%). Insiders that own company stock include David V Goeddel, Deepak Srivastava, Eli Casdin, Group Gp Lp Column III and Timothy Hoey. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tenaya Therapeutics' stock price today? One share of TNYA stock can currently be purchased for approximately $7.64. How much money does Tenaya Therapeutics make? Tenaya Therapeutics (NASDAQ:TNYA) has a market capitalization of $510.89 million. The company earns $-123,670,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. How many employees does Tenaya Therapeutics have? The company employs 106 workers across the globe. How can I contact Tenaya Therapeutics? The official website for the company is www.tenayatherapeutics.com. The company can be reached via phone at 650-825-6990 or via email at investors@tenayathera.com. This page (NASDAQ:TNYA) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.